🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Amazing presentation by Giuseppe Biondi-Zoccai on statistics at ESC congress 2024

Colchicine improves outcomes in coronary disease, but will it in heart failure? Discover more in #EHJ: academic.oup.com/eurheartj/adva… #ESCCongress #inflammation #colchicine #CVD #outcome European Society of Cardiology European Society of Cardiology Journals

B-blockers do their job in patients with previous MI and normal LVEF. Do not interrupt them! ABYSS trial

No benefits of prehospital methylprednisolone (250 mg) on infarct size in STEMI jamanetwork.com/journals/jamac…

Management of dyslipidemia in patients with comorbidities: an insightful review article by the ESC WG on Cardiovascular #Pharmacotherapy just published in #EHJPharmacotherapy 👉 bit.ly/4elh1hV EHJ-CVP Editor-in-Chief Felice Gragnano Mattia Galli DoreenTan.CVPx Rocco Montone

🚨When it is a YES ✅ and not 🚫in DOACS 💊 👉🏻 J Am Coll Cardiol 2024;83:444-465.

PCI (FFR<0.80 or stenosis >90%) reduces MACE at 2 years in Patients Undergoing Transcatheter Aortic-Valve Implantation | New England Journal of Medicine nejm.org/doi/full/10.10…

Overcoming Clopidogrel Resistance: Precision Medicine in Antiplatelet Therapy pubmed.ncbi.nlm.nih.gov/38922573 Mattia Galli #ClopidogrelResistance #Cardiology #PrecisionMedicine

Among of 11,913 patients who underwent platelet function testing (LTA) with a standardized methodology between 2004 and 2022, we found that a significant proportion of individuals present a hyper- or hypo-reactive platelet phenotype. bit.ly/47ffZBz

Semaglutide improves outcomes in patients with heart failure and mildly reduced or preserved ejection fraction - The Lancet says thelancet.com/journals/lance…

To date, PRASFIT-ACS is the only trial comparing "reduced dose of P2Y12 inhibtiros" (prasugrel 3.75 mg od) vs clopidogrel on top of aspirin in ACS. The trial’s findings led to the approval of prasugrel 3.75 mg for use in Japan. How about other countries? bit.ly/3MP1xXz

What is new in #cardiovascular #pharmacotherapy in the 2024 #ESCGuidelines on #CCS? A brief summary in collaboration with the Guideline Chairs 👉 academic.oup.com/ehjcvp/advance… #EHJPharmacotherapy Mattia Galli Felice Gragnano Christiaan JM Vrints DoreenTan.CVPx European Society of Cardiology Journals European Society of Cardiology #ESCCongress

The benefit of #anticoagulation to prevent arterial thromboembolism in #cancer patients may depend on primary tumor site and may be confined to #pancreatic cancer. Read more in #EHJPharmacotherapy 💊 academic.oup.com/ehjcvp/advance… Felice Gragnano Mattia Galli DoreenTan.CVPx

Have we come a long way in treating acute myocardial infarction? Perusing the recommendations of the 1978 Harrison's Principles of Internal Medicine will leave you appalled! futurelearn.com/courses/artifi… FutureLearn

2024 #ESCGuidelines on Chronic Coronary Syndromes: What’s new in #pharmacotherapy? The latest #PharmaPulse looks at the most important news in #EHJPharmacotherapy 👉 bit.ly/3Y5iinS EHJ-CVP Editor-in-Chief Felice Gragnano Mattia Galli Christiaan JM Vrints